ANP 022
Alternative Names: ANP-022Latest Information Update: 01 Sep 2022
Price :
$50 *
At a glance
- Originator ANP Technologies
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 31 Jul 2022 ANP Technologies has protect protection for its technologies and products including ANP 022 (ANP Technologies pipeline, July 2022)
- 27 Jul 2022 ANP 022 is available for licensing as of 27 Jul 2022. https://www.anptinc.com/partnering
- 27 Jul 2022 Preclinical trials in Prostate cancer in USA (unspecified route) (ANP Technologies pipeline, July 2022)